Sunday, May 29, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home News

Breakthrough infection could provide broad protection against current SARS-CoV-2 variants of concern

by Medical Finance
in News
Scientists discover antibody that inhibits a broad range of sarbecoviruses
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

A delta breakthrough infection generates a potent and broad neutralizing antibody response in double vaccinated individuals, according to new research. The findings were published this week in mBio, an open-access journal of the American Society for Microbiology.

In the new study, researchers collected sera from individuals attending St. Thomas’ Hospital in London who tested positive for COVID-19 and had received 2 doses of either the Pfizer or AstraZeneca vaccines. They measured how much antibody the person produced and whether the antibodies were able to prevent infection of cells by different SARS-CoV-2 variants of concern. 

The researchers found that in vaccinated individuals, there was a rapid and robust IgG recall response following breakthrough infection. This antibody response had broad neutralizing activity against current variants of concern, including omicron. The neutralization potency was 4.5-fold reduced against omicron compared to delta whereas it was 28.9-fold reduced for people who were unvaccinated.

Overall, a breakthrough infection effectively boosts the vaccine response, which could provide broad protection against current variants of concern. Recent studies show a third vaccine dose dramatically increases the neutralizing antibody response, particularly against omicron. Our data suggests a delta breakthrough infection can also act as an effective booster. This study provides insights into population immunity in double COVID-19 vaccinated individuals where SARS-CoV-2 transmission levels remain high.”


Katie Doores, Ph.D., Co-Author, Reader in the Department of Infectious Diseases, King’s College London, in the United Kingdom

Dr. Doores said they are now studying the immune response in more detail by isolating monoclonal antibodies from individuals experiencing breakthrough infections.

Source:

American Society for Microbiology

Journal reference:

Lechmere, T., et al. (2022) Broad Neutralization of SARS-CoV-2 Variants, Including Omicron, following Breakthrough Infection with Delta in COVID-19-Vaccinated Individuals. mBio. doi.org/10.1128/mbio.03798-21.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

TetraScience announces 300% ARR growth and 2021 achievements; prepares for next phase of growth

A new method to produce complex natural products in amoebae

by Medical Finance
May 28, 2022
0

A research team at the Leibniz Institute for Natural Product Research and Infection Biology - Hans Knöll Institute (Leibniz-HKI) in...

Researchers use breast milk to identify new set of protein biomarkers for cancer

Study investigates the breast milk microbiome in HIV-positive mothers

by Medical Finance
May 28, 2022
0

Infants carry a vast assemblage of bacteria, viruses and fungi in their guts. Combined, these microbes make up a complex...

Fire closes hospital and displaces staff as Colorado battles omicron

A new approach for treating multiple-drug resistant bacteria

by Medical Finance
May 29, 2022
0

Antibiotic-resistant hospital pathogens are not to be underestimated as a health risk. A research team has now introduced a new...

Researchers explore novel strategy to improve the reprogramming efficiency of human fibroblasts

Gene replacement therapy could help mend a broken heart, study suggests

by Medical Finance
May 28, 2022
0

How can you mend a broken heart? According to researchers from Japan, in some cases gene replacement therapy just might...

Malvern Panalytical expands pharmaceutical drug development solutions through the acquisition of Creoptix

UCI researchers reveal the impact of native lipids on rhodopsin signaling and regeneration

by Medical Finance
May 28, 2022
0

In a new study at University of California, Irvine, researchers have revealed the impact of native lipids on rhodopsin signaling...

Scientists unravel how blood cells mount the first line of defense against viruses

New data-driven mechanistic approach can help reduce drug costs and treat diseases

by Medical Finance
May 28, 2022
0

A new data-driven mechanistic approach that predicts cell types within tissue will help to reduce drug costs and treat diseases...

Next Post
PhoreMost and POLARISqb announce a multi-target collaboration to investigate next-generation cancer therapies

Researchers find two gene variants linked to accelerated aging in childhood cancer survivors

Study: Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains. Image Credit: nnattalli/Shutterstock

Monoclonal antibodies found to prevent lung inflammation in SARS-CoV-2-Omicron-infected mice

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Study: Utility of SARS-CoV-2 Rapid Antigen Testing for Patient Triage in the Emergency Department: A Clinical Implementation Study in Melbourne, Australia. Image Credit: Andrei Dubadzel / Shutterstock.com
    Study looks at rapid antigen vs. PCR tests in the emergency department triage
  • Study: Durable protection against SARS-CoV-2 Omicron induced by an adjuvanted subunit vaccine. Image Credit: solarseven / Shutterstock.com
    Novel nanoparticle-based COVID vaccines induce long-term neutralizing antibody response
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply